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1081-153 Detection of Peripheral Arterial Disease in Patients 
Presenting for Coronary Angiography and/or 
Intervention Patients Study (PIPS) 
Issam Moussa, Roxana Mehran, Gary S. Roubin, Sriram lye,, Thosaphol Limpijankit. 
Monica Losquadro. Lynne Glasser, Heather Klein, Steven Slack, Martin B. Leon, Jeffrey 
W. Moses, Cardiovascular Research Foundation. New York, NY, Lenox Hill Hospital, 
New York, NY 
Background: The Partners Program has defined the prevalence of peripheral arterial 
disease (PAD) in an elderly communrty-dwelling population. The prevalence of PAD in 
high cardiovascular risk population undergoing coronary angiography for suspected cor- 
onary artery disease (CAD) is not known. 
Methods: PIPS is a prospective, single center study aimed to determine the prevalence 
of undiagnosed PAD in 800 consecutive patcents presenting for coronary angiography for 
suspected CAD. Enrolled pts underwent clinical assessment, an Ankle Brachial Index 
(ABI) measurement and completed the San Diego Questionaire. and the “PARTNERS 
quality of life questionnaire. A diagnosis of PAD was based on an ABldO.9. 
Results: As of September 6, 2002, 99 patients have been enrolled. Complete data was 
available for 68 patients(mean age =66&plusmnl5 years, 69% male). Diabetes and prior 
Ml were present in 26% and 41% of pts respectively. Angina pectoris was present in 73% 
of pts while only 6% reported intermittent claudicatlon. The prevalence of PAD in the 
overall population was 26%. Prevalence of PAD according to diabetes and smoking sta- 
tus is shown in the table. 
Conclusion: PAD is relatively common in patients with suspected CAD, especially in dia- 
betics (42%). These preliminary data suggest that implementation of systematic non- 
invasive screening program for PAD in selected pts referred for coronary angiography for 
detection of PAD. Complete data on 600 pts will be available at the time of presentation. 
DM (rk25) No DM (nz63) P-Value 
PAD 42% 21% 0.047 
Active or Former Smoker (n=50) Non-Smoker (n=38) 
PAD 25% 29% “S 
1081-154 Characterizing the Young Patient With Aortic 
Dissection: Results From the International Registry of 
Aortic Dissection (IRAD) 
James L. Januzzi, Eric M. Isselbacher, Rosella Fatton, Jeanna V. Cooper, Dean E. 
Smith. Kim A. Eaale. GhristoDh A. Nienaber. Linda A. Parx? for the International Reaistrv _ 
of Aortic DissectIon, Massachusetts General Hospital, Boston, MA, University of 
Massachusetts, Worcester, MA 
Backgound: Aortic dissection (AoD) is unusual in young patients. We wished to better 
characterize the young patient with AoD. Methods: From an international registry, data 
were collected on 1076 patients diagnosed with acute AoD between 1196 and 11101. 
Patients were divided into age categories of ~40 years and 40 years and older. Unlvari- 
ate analyses comparing groups were done using Chi-squared cross tabulations for cate- 
gorical data and the Student’s t-test for continuous data. Results: 69 patients (6.4%) with 
AoD ~40 years rn age were identified. The incidence of Type A dissection among 
patients ~40 was similar to patients 40 years and older (Table 1). Compared to patients 
40 years or older in age, younger AoD patients were less likely to have a prior history of 
tradibonal AoD risk factors such as hyparienslon (HTN), or atherosclerosis, but were 
more likely to have a hlstory of Marfan syndrome, bicuspid aortic valve (BAV), or prior 
aortic surgery (see table). ClinIcal presentabons and outcomes of patients were similar 
between the two age groups, although younger patients were less likely to present with 
hypertension (28.6% vs 47.1%, p=O.O04). Relative to older patients. the sizes of the 
proximal aorta of young AoD patients were routinely significantly larger (see table). An 
analysis of patients ~40 years of age suggests that these differences in aorlic size are 
not explained by Marfan syndrome. Conclusions: Compared to older patients with AoD, 
young patients wrth AoD have unique risk factors for dissection. 
Characteristic 
Type A dissection 
History of HTN 
Atherosclerosis 
Marfan syndrome 
BAV 
AVR 
Aortic annulus (cm) 
A&C root (cm) 
Sinotubularlunction (cm) 
Ascending aorta (cm) 
Table I 
Age less than 40 
68% 
35% 
2% 
49% 
16% 
13% 
3.4*1 .o 
4.9il.7 
4.6il.6 
5.3il.6 
Age 40 and older 
62% 
74% 
33% 
2% 
3% 
5% 
3.0r0.9 
4.1*1.0 
3.9*1 .o 
4.8*1.3 
P value 
NS 
<O.OOl 
<0.001 
<0.001 
0.001 
0.01 
0.04 
0.01 
0.05 
0.03 
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1082- 146 Conditional-Dependent Effects of CVT-4325, a Novel 
Fatty Acid Oxidation Inhibitor, on Palmitate Utilization 
Heather Frasec Jeffrey J. McVeigh, Prabha N. Ibrahim, Brent K. Blackburn. Luiz 
Belardinelli, CV Therapeutics, Inc., Palo Alto, CA 
Under aerobic conditions. the heart derives more ATP from the oxidation of fatty acids 
than glucose. However, fatty acid oxidation (FOX) is less efficient than glucose oxidation 
(GOX), in that more 02 is used to oxidize fatty acids than glucose to generate an equiva- 
lent amount of ATP. Hence, agents that decrease FOX and indirectly increase GOX 
(metabolic shift) may be useful therapeutic agents to enhance cardiac efficiency in condi- 
tions of myccardial 02 deficiency. CVT-4325, a novel piperazine derivative, is a potent 
(lC50=490 nM) inhlbitor of 1-14(C]palmitoyl CoA oxidation in rat heart mitochondria. 
Thus, we sought to determme if CVT-4325 could inhibit FOX and cause a metabolic shift 
in rat isolated hearts. Hearts were perfused for 60 mln in working mode (afterload: 60 
mmHg, preload: 11.5 mmHg, rate: 5Hz) with a modified Krebs solution containing 5.5 
mM 14[C]glucose and 0, 0.4 or 1.2 mM B[H]palmitate bound to 3% BSA. Mechanical 
function was measured throughout perfusion and concentration response curves for the 
effect of CVT-4325 (O-30 PM) on LV work, FOX and GOX were determined. CVT-4325 
had no effect on LV work, cardiac output or coronary flow. CVT-4325 Inhibited FOX in a 
concentration-dependent manner. The IC50 values for inhibition of FOX by CVT-4325 
were 9.7 and 0.9 PM, in the presence of 0.4 and 1.2 mM palmitate, respectively. Inhibi- 
tion of FOX by CVT-4325 was accompanied by an increase in GOX with EC50 values of 
10.9 and 5.6 PM, in the presence of 0.4 and 1.2 mM palmitate, respectively. These data 
indicate that CVT-4325 can induce a metabolic shift in the aerobically perfused heart 
under conditions of stable workload and with a IO-fold greater potency to inhibit FOX with 
higher palmitate levels (1.2 mM). The enhanced potency of CVT-4325 at high fatty acid 
concentrations, such as those associated with myccardial ischemia and cardiac surgery, 
suggests that this new class of FOX inhibitors may possess unique, event-specific car- 
dioprotsctive properties. 
1082-147 Crucial Role of Extracellular Signal-Regulated Kinase 
Pathway in Reactive Oxygen Species-Mediated 
Endothelin-1 Gene Expression Induced by Endothelin-1 
in Rat Cardiac Fibroblasts 
Paul Chan Tzu-Hurng Cheng, Jln-Jer Chen, Taipei Medical University-Wang Fang -3 
Hospital, Taipei, Taiwan,ROC 
Background: Cardiac remodeling is a fundamental response to hypertension, myocardial 
infarction and chronic heart failure. The remodeling involves cardiac fibroblast prolifera- 
bon. Endothelin-1 (ET-l) has been implicated in the fibroblast proliferation. However, the 
mechanism involving ET-l is not clear. The present study was performed to examine the 
role of endogenous ET-l in ET-l-stimulated fibroblast proliferation and the intracellular 
signal transduction pathway of ET-l-induced ET-l gene expression. 
Methods: Rat cardiac fibroblasts were stimulated with ET-l, [3H]thymidine incorporation 
and the ET-l gene expression revealed by Northern blotting and promoter activity assay 
were examined. We also examined the effects of antioxidant pretreatment on ET-I- 
induced proliferation and the redox-sensltlve pathway in cardiac fibroblast. 
Results: ET-l-increased DNA synthesis was inhibited by ET, receptor antagonist 
(BQ485) and endothelin-converting enzyme inhibitor (phosphoramidon). ET-l gene was 
induced by ET-l. ET-l-increased intracellular reactive oxygen species (ROS) was signif- 
icantly inhibited by BQ485 and antioxidants. Antioxidants suppressed ET-l gene expres- 
sion and DNA synthesis stimulated by ET-l. ET-l activated mitogen-activated protein 
kinases (MAPKs) which were significantly inhibited by antioxidants. Only extracellular 
signal-regulated kinase (ERK) inhibitor (UO126) could inhibit ET-l-induced ET-l expres- 
slon. Truncation and mutational analysis of the ET-1 gene promoter showed that activa- 
tor protein-l (AP-I) binding site was an important ciselement in ET-l-induced ET-l 
gene expression. Antioxidants attenuated the ET-l-stimulated AP-1 binding activity. 
Conclusion: Our data suggest that ROS involved in ET-l-induced fibroblast proliferation 
and mediated ET-l-induced activation of ERK pathways, which culminated in ET-l gene 
expression. ET-1 may induce cardiac fibrosis both directly and by the autocrine mecha- 
msm in the heart. 
1082-148 Cardiorenal Actions of the Novel Direct Soluble 
Guanylate Cyclase Stimulator BAY 41-2272 in 
Experimental Congestive Heart Failure In Comparison 
to Nitroglycerin 
Guido Boerriater. Lisa C. Costello-Boerrigter. Harald Lapp, Alessandro Cataliotti, 
Toshihiro Tsuruda, Gail J. Harty, Johannes-Peter Stasch. John C. Burnett, Jr., Mayo 
Clinic and Foundation. Rochester, MN 
Background: Soluble guanylate cyclase (sGC) is a key enzyme in cardiovascular regu- 
latlon as the target of nitric oxide (NO) and the producer of the second messenger cyclic 
guanosine monophosphate. Recently, a novel drug class has been introduced with BAY 
41-2272, an orally available agent that directly stimulates sGC and sensitizes it to NO. 
Unlike conventional nitrate therapy, this effect is not associated with tachyphylaxis. In 
this study we characterized the cardiorenal actions of intravenous BAY 41.2272 !n exper- 
imental congestive heart failure (CHF) and compared it to nitroglycerin (NTG). 
